Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

NCT07500298 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Phase 1
SAR445877
FOlfox6
Bevacizimab
First Line Treatment
Metastatic Colorectal Cancer (CRC)
Microsatellite Stable

Interventions

DRUG: SAR445877
DRUG: FOLFOX6
DRUG: Bevacizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]